Info
adjuvant therapy of rcc
- Few data support adjuvant therapy.
- Although S-TRAC trial suggested ↑ 1.2 y in DFS w/ sunitinib, ASSURE & PROTECT trials w/ no benefit in DFS for sunitinib, sorafenib, or pazopanib, & ATLAS trial w/ no benefit in DFS for axitinib (NEJM 2016;375:2246; Lancet 2016;387:2008; JCO 2017;35:3916; Ann Oncol 2018;29(12):2371).
- Early data w/ adjuvant immunotherapy.
- Adjuvant pembrolizumab improves DFS (NEJM 2021;385:683)